

167 Chronic Neurologic Disorders

REFERENCES

- Chancellor AM, Warlow CP: Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. *J Neurol Neurosurg Psychiatry* 55: 1106, 1992.
- Logroscino G, Traynor BJ, Hardiman O, et al: Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. *J Neurol Neurosurg Psychiatry* 79: 6, 2008.
- Valdmanis PN, Rouleau GA: Genetics of familial amyotrophic lateral sclerosis. *Neurology* 70: 144, 2008.
- Swash M: Early diagnosis of ALS/MND. *J Neurol Sci* 160(suppl 1): S33, 1998.
- Sostarko M, Vranjes D, Brinar V, Brzovic Z: Severe progression of ALS/ MND after intervertebral discectomy. *J Neurol Sci* 160(suppl 1): S42, 1998.
- Willbourn AJ: Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. *J Neurol Sci* 160(suppl 1): S25, 1998.
- Kaufmann P, Levy G, Montes J, et al: Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. *Amyotroph Lateral Scler* 8: 42, 2007.
- Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 49: 657, 1997.
- Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 1: CD001447, 2007.
- Miller RG, Rosenberg JA, Gelinas DF, et al: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. *Neurology* 52: 1311, 1999.
- Andersen PM, Borasio GD, Dengler R, et al: EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. *Eur J Neurol* 12(12): 921, 2005.
- Chen A, Montes J, Mitsumoto H: The role of exercise in amyotrophic lateral sclerosis. *Phys Med Rehabil Clin North Am* 19: 545, 2008.
- Jacobson DL, Gange SJ, Rose NR, Graham NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol* 84: 223, 1997.
- Phillips LH: The epidemiology of myasthenia gravis. *Semin Neurol* 24: 17, 2004.
- Montero-Odasso M: Dysphonia as first symptom of late-onset myasthenia gravis. *J Gen Intern Med* 21(6): C4, 2006.
- Keeseey JC: Clinical evaluation and management of myasthenia gravis. *Muscle Nerve* 29(4): 484, 2004.
- Jani-Acsadi A, Lisak RP: Myasthenic crisis: guidelines for prevention and treatment. *J Neurol Sci* 261: 127, 2007.
- Gilbert ME, Savino PJ: Ocular myasthenia gravis. *Int Ophthalmol Clin* 47(4): 93, 2007.
- Kleiner-Fisman G, Kott HS: Myasthenia gravis mimicking stroke in elderly patients. *Mayo Clin Proc* 73: 1077, 1993.
- Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, et al: Therapeutic options in autoimmune myasthenia gravis. *Autoimmun Rev* 6(6): 373, 2007.
- Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 55(1): 7, 2000.
- Dural K, Yildirim E, Han S, et al: The importance of the time interval between diagnosis and operation in myasthenia gravis patients. *J Cardiovasc Surg (Torino)* 44(1): 125, 2003.
- Richman DP, Agius MA: Treatment of autoimmune myasthenia gravis. *Neurology* 61(12): 1652, 2003.
- Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. *Neurology* 50(6): 1778, 1998.
- Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. *Neurology* 68(11): 837, 2007.
- Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. *Cochrane Database Syst Rev* 1: CD002277, 2008.
- Baraka A: Anesthesia and critical care of thymectomy for myasthenia gravis. *Chest Surg Clin North Am* 11(2): 337, 2001.
- Barrons RW: Drug-induced neuromuscular blockade and myasthenia gravis. *Pharmacotherapy* 17(6): 1220, 1997.
- Benatar M, Kaminski HJ, Quality Standards Subcommittee of the American Academy of Neurology: Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 68(24): 2144, 2007.
- Skeie GO, Apostolski S, Evoli A, et al: Guidelines for the treatment of autoimmune neuromuscular transmission disorders. *Eur J Neurol* 13(7): 691, 2006.
- Hart JK, Sharshar T, Sathasivam S: Immunosuppressant drugs for myasthenia gravis. *J Neurol Neurosurg Psychiatry* 80(1): 5, 2009.
- Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. *Cochrane Database Syst Rev* 2: CD002828, 2005.
- Ragonese P, Aridon P, Salemi G, et al: Mortality in multiple sclerosis: a review. *Eur J Neurol* 15(2): 123, 2008.
- Weinshenker BG: Epidemiology of multiple sclerosis. *Neurol Clin* 14: 291, 1996.
- Flachenecker P: Epidemiology of neuroimmunological diseases. *J Neurol* 253(suppl 5): V2, 2006.
- Ascherio A, Munger K: Epidemiology of multiple sclerosis: from risk factors to prevention. *Semin Neurol* 28(1): 17, 2008.
- Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. *J Neuroimmunol* 194: 7, 2008.
- Kantarci OH: Genetics and natural history of multiple sclerosis. *Semin Neurol* 28(1): 7, 2008.
- Sobel RA: The pathology of multiple sclerosis. *Neurol Clin* 13: 1, 1995.
- Koch M, Uyttenboogaart M, Polman S, De Keyser J: Seizures in multiple sclerosis. *Epilepsia* 49(6): 948, 2008.
- Poser CM, Brinar VV: Diagnostic criteria for multiple sclerosis. *Clin Neurol Neurosurg* 103: 1, 2001.
- Kragt JJ, Thompson AJ, Montalban X, et al: Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. *Neurology* 70(13 Pt 2): 1084, 2008.
- Swanton JK, Rovira A, Tintore M, et al: MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurol* 6(8): 677, 2007.
- Goodin DS, Frohman EM, Garmany GPJ, et al: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology* 58: 169, 2002.
- Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. *Clin Ther* 28(4): 461, 2006.
- Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J: Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. *Neurology* 51: 529, 1998.
- Thrower BW: Relapse management in multiple sclerosis. *Neurologist* 15(1): 1, 2009.
- Dudsek A, Zettl UK: Intravenous immunoglobulin as therapeutic option in the treatment of multiple sclerosis. *J Neurol* 253(suppl 5): V50, 2006.
- Goodin DS, Cohen BA, O'Connor P, et al: Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 71(10): 766, 2008.
- Goodin DS, Arnason BG, Coyle PK et al: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 61(10): 1332, 2003.
- Frohman EM, Goodin DS, Calabresi PA, et al: The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 61(5): 602, 2003.
- Goodin DS, Frohman EM, Hurwitz B, et al: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 68(13): 977, 2007.
- Burks JS, Noronha A: Guidelines on use of anti-IFN- β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN- β antibodies in multiple sclerosis. *Eur J Neurol* 14(6): e8, 2007.
- Elovaara I, Apostolski S, van Doorn P, et al: EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neurol* 15(9): 893, 2008.
- Filippi M, Rocca MA, Arnold DL, et al: EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. *Eur J Neurol* 13(4): 313, 2006.
- Sellebjerg F, Barnes D, Filippini G, et al: EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. *Eur J Neurol* 12(12): 939, 2005.
- Pucci E, Branäs P, D'Amico R, et al: Amantadine for fatigue in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002818, 2007.
- Casetta I, Iuliano G, Filippini G, et al: Azathioprine for multiple sclerosis. *Cochrane Database Syst Rev* 4: CD003982, 2007.
- Vedula SS, Brodney-Folse S, Gal RL, Beck R: Corticosteroids for treating optic neuritis. *Cochrane Database Syst Rev* 1: CD001430, 2007.
- La Mantia L, Milanese C, Mascoli N, et al: Cyclophosphamide for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002819, 2007.
- Martinelli Boneschi F, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. *Cochrane Database Syst Rev* 4: CD002127, 2005.
- Farinotti M, Simi S, Di Pietrantonj C, et al: Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD004192, 2007.
- Mills RJ, Yap L, Young CA: Treatment for ataxia in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD005029, 2007.
- Takamori M: Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. *Biochem Biophys Res Commun* 322(4): 1347, 2004.
- Flink MT, Atchison WD: Ca²⁺ channels as targets of neurological disease: Lambert-Eaton syndrome and other Ca²⁺ channelopathies. *J Bioenerg Biomembr* 35(6): 697, 2003.
- Nakao YK, Motomura M, Fukudome T, et al: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. *Neurology* 59(11): 1773, 2002.
- Wirtz PW, Wintzen AR, Verschuuren JJ: Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. *Muscle Nerve* 32(2): 226, 2005.
- Newsom-Davis J: Lambert-Eaton myasthenic syndrome. *Rev Neurol (Paris)* 160(2): 177, 2004.
- Pascuzzi RM: Myasthenia gravis and Lambert-Eaton syndrome. *Ther Apher* 6(1): 57, 2002.

70. Verschuuren JJ, Wirtz PW, Titulaer MJ, et al: Available treatment options for the management of Lambert-Eaton myasthenic syndrome. *Expert Opin Pharmacother* 7(10): 1323, 2006.
71. Vedeler CA, Antoine JC, Giometto B, et al: Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. *Eur J Neurol* 13(7): 682, 2006.
72. Maddison P, Newsom-Davis J: Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev* 2: CD003279, 2005.
73. Feasby T, Banwell B, Benstead T, et al: Guidelines on the use of intravenous immune globulin for neurologic conditions. *Transfus Med Rev* 21(2 suppl 1): S57, 2007.
74. McCulloch CC, Kay DM, Factor SA, et al: Exploring gene-environment interactions in Parkinson's disease. *Hum Genet* 123(3): 257, 2008.
75. Tanner CM, Goldman SM: Epidemiology of Parkinson's disease. *Neurol Clin* 14(2): 317, 1996.
76. Stamey W, Jankovic J: Impulse control disorders and pathological gambling in patients with Parkinson disease. *Neurologist* 14(2): 89, 2008.
77. Factor SA: Current status of symptomatic medical therapy in Parkinson's disease. *Neurotherapeutics* 5(2): 164, 2008.
78. Eberling JL, Jagust WJ, Christine CW, et al: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology* 70(21): 1980, 2008.
79. Hallett M, Litvan I: Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. *Neurology* 53(9): 1910, 1999.
80. Uitti RJ, Wharen REJ, Turk MF: Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease. *Neurology* 51: 1755, 1998.
81. Chumakov K, Ehrenfeld E: New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. *Clin Infect Dis* 47(12): 1587, 2008.
82. Bartels MN, Omura A: Aging in polio. *Phys Med Rehabil Clin North Am* 16(1): 197, 2005.
83. Wekre LL, Stanghelle JK, Lobben B, Oyhaugen S: The Norwegian Polio Study 1994: a nationwide survey of problems in long-standing poliomyelitis. *Spinal Cord* 36(4): 280, 1998.
84. Bruno RL: Abnormal movements in sleep as a post-polio sequelae. *Am J Phys Med Rehabil* 77(4): 339, 1998.
85. On AY, Oncu J, Uludag B: Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study. *Neuro Rehabilitation* 20(4): 245, 2005.

■ USEFUL WEB RESOURCES

- ALS Association: provides information and support options for ALS patients and clinicians— <http://www.alsa.org>
- National Institute of Neurological Disorders and Stroke: NINDS Amyotrophic Lateral Sclerosis Information Page—<http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm>
- Post-Polio Health International: general information on living independently with polio, as well as research on amelioration of disease symptoms—<http://www.post-polio.org/>
- Myasthenia Gravis Foundation of America, Inc.: symptomatic and therapeutic information for myasthenia gravis patients and clinicians— <http://www.myasthenia.org>
- National Institute of Neurological Disorders and Stroke: fact sheet on myasthenia gravis, as well as contact information for support organizations—http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm
- eMedicine from webMD, Myasthenia Gravis: Treatment & Medication—<http://emedicine.medscape.com/article/793136-treatment>
- National Multiple Sclerosis Society: community support, fundraising, research prospects, information on multiple sclerosis—<http://www.nationalmssociety.org/index.aspx>
- National Institute of Neurological Disorders and Stroke: NINDS Multiple Sclerosis Information Page with information on the diagnosis and treatment of multiple sclerosis, along with organization and contact information—http://www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm
- National Parkinson Foundation: information for patients and physicians and research prospects—<http://www.parkinson.org>